Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy

  • Masaaki Saito
  • Tomohiro Iida
  • Mariko Kano
  • Kanako Itagaki
Retinal Disorders

DOI: 10.1007/s00417-013-2323-6

Cite this article as:
Saito, M., Iida, T., Kano, M. et al. Graefes Arch Clin Exp Ophthalmol (2013) 251: 2099. doi:10.1007/s00417-013-2323-6

Abstract

Background

To clarify the efficacy of combined therapy with intravitreal ranibizumab injections and photodynamic therapy (PDT) in patients with symptomatic polypoidal choroidal vasculopathy (PCV).

Methods

We retrospectively reviewed 57 treatment-naïve eyes of 57 patients. Thirty-two patients were treated with standard fluence PDT (PDT group), and 25 patients were treated with three consecutive monthly intravitreal injections of ranibizumab and standard fluence PDT (ranibizumab plus PDT group). All patients were followed for at least 24 months.

Results

In the ranibizumab plus PDT group, the mean best-corrected visual acuity (BCVA) levels of decimal (logMAR equivalent) significantly improved from 0.30 (0.52) at baseline to 0.55 (0.26) at 24 months (P < 0.001). In the PDT group, the BCVA levels stabilized from 0.26 (0.58) at baseline to 0.25 (0.60) at 24 months. The mean changes in the BCVA in the ranibizumab plus PDT group and the PDT group were improvement of 2.63 lines and decline of 0.16 lines respectively (P = 0.010). The mean number of PDTs at 24 months in the ranibizumab plus PDT group and the PDT group were 1.4 and 2.6 respectively. Increased subretinal hemorrhages were seen in eight (18.0 %) eyes, all of which were belonging to the PDT group.

Conclusions

Combined intravitreal ranibizumab and PDT was significantly more effective in maintaining and improving VA for PCV patients compared with PDT monotherapy over 24 months.

Keywords

Polypoidal choroidal vasculopathy Ranibizumab Photodynamic therapy Vascular endothelial growth factor Indocyanine green angiography Age-related macular degeneration Retinal pigment epithelial detachment Optical coherence tomography Retinal pigment epithelium Bevacizumab 

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Masaaki Saito
    • 1
  • Tomohiro Iida
    • 1
    • 2
  • Mariko Kano
    • 1
  • Kanako Itagaki
    • 1
  1. 1.Department of OphthalmologyFukushima Medical University School of MedicineFukushimaJapan
  2. 2.Department of OphthalmologyTokyo Women’s Medical University School of MedicineTokyoJapan

Personalised recommendations